Stable liquid bortezomib formulations

Abstract

Described herein are liquid compositions comprising: bortezomib; mannitol in an amount up to about 50 mg/mL; and a pharmaceutically acceptable carrier, wherein the liquid composition is for intravenous or subcutaneous use; and wherein the liquid composition comprises not more than (NMT) 1.0% of Impurity-E; Impurity-L; Impurity-J; Impurity-F; Impurity-I; or Impurity-U; and NMT than 3.0% of Total Impurities. Methods of making and using these compositions are also described herein.

Dependencies are inferred from the claim text.